Article Text

Download PDFPDF
Villoglandular Papillary Adenocarcinoma of the Cervix: A Series of 28 Cases Including Two With Lymph Node Metastasis
  1. Isam M. Lataifeh, MD, CGO*,,
  2. Maysa Al-Hussaini, MD,
  3. Catherine Uzan, MD§,
  4. Imad Jaradat, MD,
  5. Pierre Duvillard, MD and
  6. Philippe Morice, MD#,**
  1. *Department of Obstetrics and Gynecology, Jordan University of Science and Technology, Irbid, Jordan; Departments of
  2. Surgery and
  3. Pathology, King Hussein Cancer Center, Amman, Jordan;
  4. §Department of Surgery, Institute Gustave Roussy, Paris, France;
  5. Radiation Therapy, King Hussein Cancer Center, Amman, Jordan;
  6. Department of Pathology, Institute Gustave Roussy, Paris in France; and
  7. #Department of Surgery, Institute Gustave Roussy, Paris, France; Unit INSERM 10-30, Villejuif, France; and
  8. **University Paris Sud, Le Kremlin Bicêtre, France.
  1. Address correspondence and reprint requests to Isam M. Lataifeh, MD, CGO, Department of Obstetrics and Gynecology, Jordan University of Science and Technology, PO Box 3030, Irbid 22110, Jordan. E-mail: isam_l{at}


Objective To investigate the clinicopathologic features, the management, and the outcome of villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix.

Methods A retrospective review of patients’ clinical characteristics, pathology, and the disease management, together with outcome information.

Results A total of 28 patients with VGPA were treated. The median age of the patients was 38 years with a range of 26 to 65 years. Sixteen of the 21 patients presented with abnormal bleeding, and 5 patients had an abnormal Papanicolaou (Pap) test result. Nineteen patients had International Federation of Gynecology and Obstetrics stage IB disease, and 5 patients had stage IIB disease. Two of 24 patients, where the lymph node status was known, had positive nodes. Twenty patients underwent different types of radical surgery with or without pelvic radiotherapy, and 8 patients received platinum-based chemotherapy and pelvic radiotherapy with no surgery. The follow-up ranged from 5 to 168 months with a median of 35 months. Twenty–one patients are alive with no evidence of recurrent disease, 5 patients have died because of the disease recurrence, and 2 patients were lost to follow-up. The overall and disease-free 5-year survival for these patients was 82% and 75%, respectively.

Conclusion This study confirms the excellent prognosis of VGPA overall compared to the common forms of cervical cancer, but the prognosis is related to stage and pathology. A large multicenter prospective study is warranted to determine the most appropriate treatment for the disease. Until then, a meta-analysis on the subject would be of benefit.

  • Adenocarcinoma
  • Cervix
  • Papillary
  • Villoglandular
  • Lymph node

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.